

# EVENTITY<sup>®</sup> was studied with nearly 12,000 women with postmenopausal osteoporosis in three phase 3 trials<sup>1,2</sup>



## FRAME

Placebo-controlled fracture study in postmenopausal osteoporotic women<sup>3</sup>



## ARCH

Head-to-head fracture study vs alendronate in post-fracture women<sup>4</sup>



## STRUCTURE

Active-controlled BMD study vs teriparatide in women at high risk of fracture transitioning from oral bisphosphonates<sup>2</sup>



Scan the QR Code for Eventity<sup>®</sup> Abbreviated Prescribing Information

  
**EVENTITY<sup>®</sup>**  
(romosozumab) injection

**References:** **1.** EVENTITY<sup>®</sup> (romosozumab) Malaysia Prescribing Information MYEVEPI01, revised May 2021. **2.** Langdahl BL, et al. Lancet 2017;390:1585-1594. **3.** Cosman F, et al. N Engl J Med 2016;375:1532-1543. **4.** Saag KG, et al. N Engl J Med 2017;377:1417-1427.

© 2022 Amgen Inc. All rights reserved.

MY-00653-EVE-2022-Jun

**AMGEN<sup>®</sup>**